tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

Faron Pharmaceuticals’ Bexmarilimab Shows Promising Results in High-Risk Myelodysplastic Syndrome, Supporting Buy Rating
RatingsFaron Pharmaceuticals’ Bexmarilimab Shows Promising Results in High-Risk Myelodysplastic Syndrome, Supporting Buy Rating
22h ago
Faron Pharmaceuticals’ Bexmarilimab Shows Promising Results in HR-MDS Treatment
PremiumCompany Announcements
Faron Pharmaceuticals’ Bexmarilimab Shows Promising Results in HR-MDS Treatment
1d ago
Faron Pharmaceuticals Registers New Shares to Enhance Market Position
PremiumCompany Announcements
Faron Pharmaceuticals Registers New Shares to Enhance Market Position
18d ago
Faron Pharmaceuticals Approves New Share Issuance Amid Convertible Bond Strategy
PremiumCompany Announcements
Faron Pharmaceuticals Approves New Share Issuance Amid Convertible Bond Strategy
18d ago
Faron Pharmaceuticals Announces Option Exercise and Equity Issue
PremiumCompany Announcements
Faron Pharmaceuticals Announces Option Exercise and Equity Issue
1M ago
Faron Pharmaceuticals Oy’s Bexmarilimab Shows Promise in HR-MDS Trials with FDA Support, Reinforcing Buy Rating
PremiumRatingsFaron Pharmaceuticals Oy’s Bexmarilimab Shows Promise in HR-MDS Trials with FDA Support, Reinforcing Buy Rating
1M ago
Faron Pharmaceuticals Updates Half-Year Financial Results and Achieves Key Milestones
Premium
Company Announcements
Faron Pharmaceuticals Updates Half-Year Financial Results and Achieves Key Milestones
1M ago
Faron Pharmaceuticals Achieves Key Milestones in H1 2025
Premium
Company Announcements
Faron Pharmaceuticals Achieves Key Milestones in H1 2025
2M ago
Faron Pharmaceuticals to Announce Half-Year Financial Results
PremiumCompany Announcements
Faron Pharmaceuticals to Announce Half-Year Financial Results
2M ago
Faron Pharmaceuticals Advances Bexmarilimab in HR-MDS Treatment Following FDA Guidance
PremiumCompany Announcements
Faron Pharmaceuticals Advances Bexmarilimab in HR-MDS Treatment Following FDA Guidance
2M ago
Faron Pharmaceuticals Approves Share Subscription for Bond Amortisation
PremiumCompany Announcements
Faron Pharmaceuticals Approves Share Subscription for Bond Amortisation
3M ago
Buy Rating Affirmed for Faron Pharmaceuticals Oy: Promising Bexmarilimab Trial Results and Strategic Advancements
PremiumRatings
Buy Rating Affirmed for Faron Pharmaceuticals Oy: Promising Bexmarilimab Trial Results and Strategic Advancements
3M ago
Faron Pharmaceuticals Achieves 43% Remission Rate in BEXMAB Trial
PremiumCompany AnnouncementsFaron Pharmaceuticals Achieves 43% Remission Rate in BEXMAB Trial
3M ago
Faron Pharmaceuticals Achieves 43% Remission Rate in HR-MDS Trial
Premium
Company Announcements
Faron Pharmaceuticals Achieves 43% Remission Rate in HR-MDS Trial
3M ago
Faron Pharmaceuticals Chairman Increases Shareholding
Premium
Company Announcements
Faron Pharmaceuticals Chairman Increases Shareholding
4M ago
Faron Pharmaceuticals Oy’s Bexmarilimab: A Promising Buy with Transformative Potential in MDS Treatment
PremiumRatings
Faron Pharmaceuticals Oy’s Bexmarilimab: A Promising Buy with Transformative Potential in MDS Treatment
4M ago
Faron Pharmaceuticals CEO Increases Stake in Company
PremiumCompany Announcements
Faron Pharmaceuticals CEO Increases Stake in Company
4M ago
Faron Pharmaceuticals Founders Donate and Sell Shares to Support Medical Research
PremiumCompany Announcements
Faron Pharmaceuticals Founders Donate and Sell Shares to Support Medical Research
5M ago
Promising Phase 2 Results and Regulatory Progress Drive Buy Rating for Faron Pharmaceuticals’ Bexmarilimab
PremiumRatings
Promising Phase 2 Results and Regulatory Progress Drive Buy Rating for Faron Pharmaceuticals’ Bexmarilimab
5M ago
Faron Pharmaceuticals Registers Over 5 Million New Shares to Bolster Market Position
PremiumCompany AnnouncementsFaron Pharmaceuticals Registers Over 5 Million New Shares to Bolster Market Position
5M ago
Faron Pharmaceuticals Converts Special Rights into Shares for Bond Amortisation
Premium
Company Announcements
Faron Pharmaceuticals Converts Special Rights into Shares for Bond Amortisation
5M ago
Faron Pharmaceuticals Issues Treasury Shares for Convertible Bond Flexibility
Premium
Company Announcements
Faron Pharmaceuticals Issues Treasury Shares for Convertible Bond Flexibility
5M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >